Orsight Pharma Overview
Orsight Pharma develops a breakthrough small molecule treatment designed to preserve vision and prevent blindness through a novel VEGF-independent mechanism. This drug offers a ray of hope, especially for those who have not seen satisfactory results with existing treatments. The company's product not only stands to benefit patients unresponsive to current therapies but also has the potential to enhance visual outcomes when used in combination with them.
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.1M |
| Last funding | Undisclosed |
| Stage | Pre-Seed |
| Rounds | 2 |
| Investors | 1 |
Team Members
1
Employees: 1-10
Web & Social Links
Locations
Nazareth, Israel
Photos & Videos
No files yet
Orsight Pharma Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
—Core Technology
—Orsight Pharma Financials
Orsight Pharma Lifecycle
Orsight Pharma News
0 articlesNo news articles.
Orsight Pharma Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 3 classification IDs that could be used for matching.
Orsight Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 67/100 |
| Missing | sector, tags, homepage, video or image, news, markets, not claimed |
| BI Verification | Matan Eblagon |
| Registrar ID | 516879756 |
| Creator | Tamar Harris Kedar |
| Creator email | tamar@ngt-healthcare2.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-06-23T00:00:00.000Z |
| Created | 2024-06-18T00:00:00.000Z |